New York, Feb 12, 2026, 07:12 ET — Premarket
- Amazon Pharmacy is widening same-day prescription delivery to more U.S. communities
- One Medical added a lab-results feature aimed at simplifying routine bloodwork
- Traders are still fixated on AI-related spending and Friday’s inflation print
Amazon.com Inc shares are headed into Thursday after falling 1.4% in the prior session, closing at $204.08.
The stock has turned into a referendum on how much investment investors will stomach from Big Tech, and how soon it shows up in cash. In that mood, even routine product and service updates can become part of the trading tape.
Healthcare is one of those battlegrounds. Amazon has been pushing further into prescriptions and primary care, leaning on its logistics network and the One Medical footprint at the same time.
Amazon Pharmacy will expand same-day prescription delivery to about 4,500 U.S. cities and towns by the end of 2026, adding nearly 2,000 new communities, Reuters reported. The company bought online pharmacy PillPack in 2018, and it has been using its One Medical clinics to test in-person pickup through electronic kiosks, the report said. (Reuters)
“Patients shouldn’t have to choose between speed, cost, and convenience,” said John Love, vice president of Amazon Pharmacy, as the company pitched the rollout as a response to access problems in parts of the country. (Amazon News)
Amazon One Medical, meanwhile, said it launched “Health Insights,” a beta feature that analyzes more than 50 biomarkers from standard bloodwork and serves up recommendations, developed in partnership with Lifeforce. “Health Insights brings clarity to complex health data,” said Andrew Diamond, chief medical officer at Amazon One Medical, in the announcement. (US Press Center)
A separate filing showed Amazon beneficially owns 11,753,896 shares — a 5.3% stake — in BETA Technologies, held through a wholly owned subsidiary, Amazon.com NV Investment Holdings. (SEC)
All of that is landing on a market still chewing on Amazon’s spending outlook. The company projected about $200 billion in capital expenditures in 2026, up from $131 billion in 2025, largely to build artificial-intelligence infrastructure, Reuters reported. “Amazon has to invest at these levels just to stay in the race,” D.A. Davidson analyst Gil Luria said; another analyst warned the 2026 spend could run ahead of operating cash flow. (Reuters)
Amazon’s cloud unit remains central to the argument, because it is where investors look for operating leverage when spending rises. If demand stays hot but costs outrun revenue, the stock can get pinned even with solid growth.
Rates are the other pressure point. A stronger U.S. jobs report has cooled expectations for near-term Federal Reserve rate cuts, and attention has shifted to inflation, Reuters’ Morning Bid said. (Reuters)
But the setup cuts both ways. If inflation surprises on the high side and bond yields jump, high-valuation tech could take another hit; if inflation cools, the market may give heavy spenders more room. Amazon also faces the slower grind of building healthcare share against entrenched pharmacy players and a regulated system.
The next macro catalyst is Friday: the U.S. Consumer Price Index for January is scheduled for release on Feb. 13 at 8:30 a.m. Eastern time, the Labor Department’s schedule shows. (Bls)
